DelveInsight’s "Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2034" report delivers an in-depth ...

Have you ever heard of a condition where your immune system gets too overprotective and ends up causing more harm than good? That’s what happens in Antiphospholipid Antibody Syndrome (APS). It’s a ...

IGM Biosciences, Inc.’s IGMS share price has dipped by 6.85%, which has investors questioning if this is right time to buy.

Covert or latent Toxoplasma gondii infection is significantly correlated with chronic kidney disease, according to research ...

The human immune system is highly complex and well-equipped to combat most bacteria. However, in some instances bacteria can cause life-threatening infections and the increase of antibiotic-resistant ...

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, announced that Randall ...

The levels of anti-COPT1-IgG and anti-COPT1-IgM autoantibodies were significantly higher in patients with NSCLC (P<0.05). Anti-COPT1-IgG and anti-COPT1-IgM could discriminate NSCLC from NC with area ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Non-Commercial (NC): Only non-commercial uses of the work are permitted. No ...

Inebilizumab-cdon is the first FDA-approved treatment for IgG4-related disease, targeting CD19+ B cells to reduce inflammation and fibrosis. The MITIGATE trial showed inebilizumab significantly ...

Unlike mammalian immunoglobulins, which are classified into five major types based on their function and structure, members of the IgSF in invertebrates exhibit a much broader diversity. Nevertheless, ...

Phase 3 VISIONARY study met its primary endpoint at the prespecified interim analysis; sibeprenlimab demonstrated a statistically significant and clinically meaningful reduction in 24-hour uPCR after ...